Clinical Trials Logo

Clinical Trial Summary

Human recombinant endostatin preclinical studies have shown that the drug can inhibit endothelial cell proliferation, angiogenesis and tumor growth, still can directly induce lung cancer cell apoptosis, multiple clinical studies in human recombinant endostatin combined with chemotherapy treatment showed good antitumor efficacy and good safety.S1 is an oral fluorouracil derivative and an improved preparation of the antitumor drug tegafur.Multiple clinical studies have reported that S1 alone or S1 combined with chemotherapy is effective in Non small cell lung cancer(NSCLC).Unfortunately, none of the prospective clinical studies to date have systematically validated the safety and efficacy of antiangiogenic drugs combined with chemotherapy in patients with advanced pulmonary SCC.The investigators expect that endu combined with S1 will increase the efficacy of advanced lung squamous cell carcinoma.The purpose of this study was to evaluate the objective remission rate and safety of entu combined with oral S1 in the treatment of advanced lung squamous cell carcinoma.


Clinical Trial Description

In this study, the investigatorse enrolled patients with advanced lung squamous cell carcinoma to explore the safety and efficacy of sequential local radiotherapy combined with endodontic therapy.Plan to enroll 60 cases.For those who meet the inclusion criteria, medical history collection, physical examination, hematological examination and general imaging examination shall be completed before inclusion.Radiotherapy was performed with a cyberknife or accelerator stereotactic radiotherapy, which lasted 3-10 days.After the end of radiotherapy,S1 60mg, BID, day 1-28, as taken orally, and repeated every 6 weeks, with concurrent Endostar therapy: 210mg was used by intravenous infusion for 7 consecutive days during each cycle of chemotherapy, and 30mg was used every 24 hours.Treatment-related toxicity, treatment response and survival were followed up during treatment.Drug treatment until the tumor progresses, or there is an intolerable treatment-related toxicity, or no tolerance to further treatment.The treatment lasts for up to 3 years with good toxicity tolerance.During the treatment, the dose of teggio and endu is not adjusted. If serious adverse reactions occur, the drug should be treated actively and delayed.If the investigator determines that the treatment-related toxicity cannot be tolerated, the treatment is discontinued. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04274270
Study type Interventional
Source Peking University Third Hospital
Contact
Status Not yet recruiting
Phase N/A
Start date April 1, 2020
Completion date January 30, 2023

See also
  Status Clinical Trial Phase
Completed NCT04059809 - Photobiomodulation for Breast Cancer Radiodermatitis Phase 2/Phase 3
Recruiting NCT05543239 - Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation on Radiotherapy-Related Neuropathic Pain N/A
Terminated NCT04535908 - Hypofractionated Radiotherapy in Prostate Cancer Patients Aged 75 Years or Older. N/A
Recruiting NCT04115267 - Attribution of Toxicities Due to Radiotherapy and Immuno-Biological Therapies
Recruiting NCT05820633 - Pelvic Nodes Ultra-Hypo vs Conventionally Fractionated IMRT With HDR Boost in Prostate Cancer. N/A
Completed NCT05880446 - PROstate CAncer Radiotherapy - Bowel Quality of Life (PROCAR-BQ) N/A
Recruiting NCT05724004 - Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB) N/A
Recruiting NCT04612907 - Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer N/A
Recruiting NCT05762900 - Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients Phase 2
Recruiting NCT03613506 - The Role and Intervention of TGF-β in Abdominal Radiation Injury Phase 2
Completed NCT06353724 - Comparison Between the Effect of Using Conventional and Digital Oral Positional Radiation Stent N/A
Not yet recruiting NCT05548504 - Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC Phase 2
Recruiting NCT05224297 - Patient Experience Data in Radiation Oncology
Recruiting NCT05776147 - Radiotherapy With Extreme Hypofractionation in Patients With Breast Cancer in Brazil: a Retrospective Cohort Study
Completed NCT04842409 - Safety of Ultra-hypofractionated Whole Breast Irradiation After Breast-conserving Surgery
Recruiting NCT03742687 - Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC N/A
Not yet recruiting NCT05614700 - Prostate Reirradiation Toxicity Outcomes Feasibility Study N/A
Completed NCT04027543 - Neoadjuvant Chemotherapy or Chemoradiotherapy in Resectable Oesophageal Carcinoma(NewEC Study)
Recruiting NCT05354596 - A Multicenter Phase II Study of Stereotactic Radiotherapy for Centrally Located Lung Tumors (STRICT-LUNG STUDY) and Ultra-centrally Located Lung Tumors (STAR-LUNG STUDY). N/A
Recruiting NCT03378856 - Evaluation of Technological Innovation in Radiotherapy